Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate-to-severe plaque psoriasis in adults, receives health insurance benefits in Korea for treating adult patients with chronic severe plaque psoriasis.The first TYK2 inhibitor and once-daily oral treatment approved for modera
Merck Biopharma Korea's superovulation induction injection Pergoveris (follitropin alpha) will receive expanded reimbursement to treat patients with severe luteinizing hormone (LH) and follicle-stimulating hormone (FSH) deficiencies from Monday.Pergoveris is a superovulation induction injection cont
Leqvio (inclisiran), a cholesterol management drug that requires only two subcutaneous injections per year, is preparing to land in Korea.The Ministry of Food and Drug Safety (MFDS) is reportedly reviewing Novartis Korea's application to license Leqvio. Approval is expected as early as the first hal
MSD Korea said its new 15-valent pneumococcal protein conjugate vaccine, Vaxneuvance, will be available for free at hospitals and clinics nationwide starting Monday as part of the National Immunization Program (NIP) for children.Vaxneuvance is indicated for preventing invasive disease and pneumonia
Daewoong Pharmaceutical's new Co-CEO Park Seong-soo, promoted from vice president, vowed to achieve 1 trillion won ($741.8 million) in operating profit under his leadership.Park was appointed as the company's new co-CEO following a board meeting held on Thursday.This strategic move transitions the c
After the plans to integrate Hanmi Group with OCI Holdings fell through, Hanmi officials withdrew from their nominations as internal directors at OCI Holdings.This development came ahead of OCI Holdings’ annual shareholders' general meeting on Friday, signaling a significant shift in the relationshi
Starting April 1, Soliris, a complement C5 inhibitor, will be reimbursed for neuromyelitis optica spectrum disorder (NMOSD), expanding its health insurance coverage beyond paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).On Friday, AstraZeneca Korea announced t
Starting next month, health insurance benefits will be applied to treating metastatic breast and gastric cancers with Enhertu (trastuzumab deruxtecan) in Korea. On Thursday, the Ministry of Health and Welfare convened the Health Insurance Policy Deliberation Committee and approved the revised “Drug
D&D Pharmatech said Thursday that DD01, an injectable treatment for metabolic-associated steatohepatitis (MASH) being developed by the company, has received fast-track designation from the U.S. Food and Drug Administration. This is the second MASH treatment developed by a Korean company to receive t
In a pivotal shareholders' meeting of Hanmi Science on Thursday, the control tower within the Hanmi Group, the sons --Coree Group Chairman Lim Jong-yoon and Hanmi Fine Chemical CEO Lim Jong-hoon -- of the founding family secured a significant victory in the boardroom struggle against their mother an
The treatment of biliary tract cancer, one of the cancers with a poor prognosis, is changing rapidly. Immunotherapies and targeted anticancer drugs have been developed in a rush. However, none of them have been covered by health insurance in Korea, and patients and medical workers complain that the
Celltrion, a Korean biopharmaceutical giant, said it has launched a 20-mg dosage formulation of its biosimilar Yuflyma (adalimumab) to treat autoimmune diseases in pediatric patients in the U.S.Yuflyma 20mg is the same high-concentration (100mg/mL) formulation as the 40mg and 80 mg, which were launc
Takeda Pharmaceuticals Korea said on Thursday that Livtencity (ingredient: maribavir), a tablet for cytomegalovirus (CMV) infection and disease after transplantation, will be covered by Korean national health insurance starting April 1.Livtencity is an antiviral pill developed to treat CMV infection
HK inno.N said it plans to present the interim preclinical research findings on IN-119873, its next-generation allosteric EGFR-tyrosine kinase inhibitor (EGFR-TKI) candidate, targeting non-small cell lung cancer (NSCLC) patients with the L858R genetic mutation, during the upcoming annual meeting of
Pfizer Korea’s attempts to expand reimbursement for its third-generation ALK inhibitor Lorviqua (lorlatinib) do not seem to bear fruit easily, according to industry sources.Some analysts have speculated that Pfizer Korea might have made a strategic choice in the drug price negotiations due to Lorviq
Hanmi Group Chairman Song Young-sook and her daughter have gained a decisive edge in the ongoing management conflict within the founding family after securing support from the National Pension Service (NPS), which has emerged as a deciding factor in this corporate governance battle.On Tuesday evenin
A local court denied the preliminary injunction filed by the late Hanmi founders' sons—Coree Group Chairman Lim Jong-yoon and Hanmi Fine Chemical CEO Lim Jong-hoon—to halt the issuance of new shares to OCI Holdings. The merger between Hanmi Pharmaceutical Group and OCI Group is currently led by Hanm
The health authorities recently designated “systemic pustular psoriasis” as a rare disease and included it in this year's special calculation targets, opening the way for the use of Spevigo (spesolimab) for the disease’s treatment.However, a big hurdle of insurance benefits remains before its treatm
Despite predictions that its high cost as a premium vaccine would be a barrier to market expansion, GSK's shingles vaccine, Shingrix, has claimed the top sales spot in the market in its first year of release.Shingles is caused when the varicella-zoster virus (VZV), which causes chickenpox, becomes r
Dong-A ST said it signed a joint sales agreement with Yuyu Pharma on Monday for the peripheral circulation improvement drug Tanamine Tablet at the latter’s headquarters in Shindang-dong, Jung-gu, Seoul.The two companies' senior managers, including Dong-A ST CEO Kim Min-young and Yuyu Pharma CEO Yu W